Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Operating Expenses: 2013-2024

Historic Operating Expenses for CytomX Therapeutics (CTMX) over the last 12 years, with Dec 2024 value amounting to $113.1 million.

  • CytomX Therapeutics' Operating Expenses fell 25.89% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.4 million, marking a year-over-year decrease of 24.62%. This contributed to the annual value of $113.1 million for FY2024, which is 5.02% up from last year.
  • Per CytomX Therapeutics' latest filing, its Operating Expenses stood at $113.1 million for FY2024, which was up 5.02% from $107.7 million recorded in FY2023.
  • CytomX Therapeutics' Operating Expenses' 5-year high stood at $154.5 million during FY2022, with a 5-year trough of $107.7 million in FY2023.
  • Moreover, its 3-year median value for Operating Expenses was $113.1 million (2024), whereas its average is $125.1 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 30.29% in 2023, then increased by 5.02% in 2024.
  • CytomX Therapeutics' Operating Expenses (Yearly) stood at $149.0 million in 2020, then grew by 2.94% to $153.4 million in 2021, then increased by 0.75% to $154.5 million in 2022, then tumbled by 30.29% to $107.7 million in 2023, then climbed by 5.02% to $113.1 million in 2024.